What's New in Insulin?
What's New in Insulin?
The webcast activity "What's New In Insulin?" was originally presented at CEU 2015, the Endocrine Society's 67th Clinical Endocrinology Update Meeting, held in Miami, FL on September 11, 2015.
Expert faculty discussed recent advances in the practical applications of new tools and potential strategies in insulin therapy for diabetes management.
This activity was supported by an educational grant from Novo Nordisk Inc.
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.
Upon completion of this educational activity, learners will be better able to:
- Select and optimize the most appropriate basal insulin strategy taking recent advancements into consideration
- Apply therapies in combination with insulin and discuss emerging options to optimize treatment of patients with diabetes
- Discuss emerging insulin formulations and delivery devices
Carol H. Wysham, MD – Program Director
Clinical Associate Professor of Medicine
University of Washington School of Medicine
Section Head, Department of Diabetes and Endocrinology, Rockwood Clinic
Jack L. Leahy, MD
Professor of Medicine
Chief of Endocrinology, Diabetes and Metabolism
University of Vermont
Mark R. Burge, MD
Professor of Medicine
Deputy Director, University of New Mexico
Clinical & Translational Science Center
Albuquerque, New Mexico
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Carol Wysham, MD (Chair): Consultant and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Janssen Pharmaceuticals, Sanofi-Aventis; Consultant, Dance Pharmaceuticals; Speaker, Novo Nordisk
Jack L Leahy, MD: Advisory Board Member, Janssen, Merck, Novo Nordisk, Roche, Sanofi
Mark Burge, MD: Research Grant Support, Grifols Inc., Sanofi Inc., VisionQuest, LLC
The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships:
Irl B Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
DISCLAIMERS USE OF PROFESSIONAL JUDGMENT:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications. POLICY ON
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.00 AMA PRA Category 1 Credits™
- 2.00 CME Certificate of Participation